2026 - Introduced
New Jersey A1821/S.B. 4283
  • Prohibits health insurers from denying coverage of non-opioid prescription drugs in favor of opioid prescription drugs.
State Employee Health Plan ParityMedicaid Parity
Read BillRead Senate Bill
2024 - Introduced
New Jersey A4682
  • Prohibits health insurers, Medicaid and School Employees’ Health Benefits from denying coverage of non-opioid prescription drugs in favor of opioid prescription drugs. Further, formularies are prohibited from disincentivizing the use of non-opioids with respect to coverage or cost-sharing.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2026 - Introduced
Oklahoma S.B. 1563
  • Requires the state Medicaid program and regulated health plans cover FDA-approved non-opioid pain treatments without requiring patients to try opioids first and without less favorable coverage or higher cost-sharing than opioid treatments.
  • Prohibits Medicaid formularies and carrier utilization controls from disadvantaging clinically appropriate non-opioid pain treatments, such as through prior authorization or step therapy, compared to opioids.
  • Directs the state to leverage grants and opioid settlement funds to support education on non-opioid options.
Medicaid ParityState Regulated Commercial Parity
Read Senate Bill
2024 - Passed
Oklahoma S.B.1344
  • Requires that the state Medicaid preferred drug list and utilization management not disadvantage a non-opioid pain medication relative to an opioid pain medication.
  • Requires the state government to seek grant opportunities relating to education and services regarding non-opioid medications.
  • Provides that the state may assist in using opioid settlement funds to support education regarding non-opioid alternatives.
Medicaid ParityEducation
Read Bill
2025 - Introduced
Oregon S.B.598
  • Requires health insurers and Medicaid establish parity for opioids and non-opioid treatments.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2026 - Introduced
Pennsylvania H.B. 2060/S.B. 1196
  • Requires Medicaid and commercial insurers to provide pain parity by ensuring FDA-approved non opioid drugs are not disadvantaged in coverage, cost sharing, or utilization controls compared with opioids, applying upon FDA approval.
Medicaid ParityState Employee Health Plan Parity
Read House BillRead Senate Bill
2025 - Introduced
South Carolina S.B. 161/H.B. 4165
  • Prohibits preferencing coverage of an opioid prescription treatment over a non-opioid treatment and requires the South Carolina Department of Public Health to create educational materials and guidelines for practitioners about non-opioid alternative treatment options.
Medicaid ParityEducation
Read Senate BillRead House Bill
2025 - Introduced
South Dakota H.B.1137
  • Ensures FDA-approved non-opioid drugs are not disadvantaged or discouraged with respect to coverage of an opioid on the state preferred drug list.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Passed
Tennessee S.B.2011/H.B.2903
  • Prevents opioids from being preferred over a non-opioid pain medication on TennCare's preferred drug list and makes a non-opioid available immediately upon FDA-approval.
  • Requires state Medicaid departments to ensure prescribers and hospitals are reimbursed for providing non-opioid medications.
  • Prohibits health insurers from denying coverage of a non-opioid prescription drug in favor of an opioid, when prescribed.
Medicaid Parity
Read House BillRead Senate Bill
2025 - Introduced
Utah S.B. 331
  • Prohibits Medicaid and health insurers from imposing more restrictive or extensive prescription drug utilization management practices for a non-opioid drug than the least restrictive or extensive practice applicable to any opioid.
  • Requires that if Utah Department of Health and Human Services funding is available, pamphlets about opiates should include information about non-opioid drug alternatives.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Introduced
Virginia H.B.1765
  • Prohibits health insurers from imposing cost-sharing, prior authorization, step therapy, or other coverage limitations on a covered FDA-approved non-opioid drug.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Introduced
Virginia S.B.800
  • Ensures that no non-opioid approved by the FDA shall be disadvantaged or discouraged relative to opioids, including through prior authorization or step therapy.
Medicaid Parity
Read Bill